https://www.thebionews.net/news/articleView.html?idxno=27022

Channel
[IV Research]
@IVResearch
On this record: Growth · Engagement · Posts · Citations · Cite this entry
2,474subscribers
-2 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 1,000–3,162.
Register entry
| Telegram ID | -1001738851765 |
|---|---|
| Type | Channel |
| Username | @IVResearch |
| Created | Between 1 December 2021 and 31 March 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 7 August 2026 |
| Last confirmed live | 11 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 11 August 2026 |
| On Telegram | t.me/IVResearch |
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 11 Aug 2026, 05:18 | 2,474 | -2 |
| 7 Aug 2026, 14:33 | 2,476 | no change |
| 7 Aug 2026, 14:26 | 2,476 | first reading |
Engagement
20 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.
- ERR · 30 days
- 12.1%
- avg views ÷ 2,474 subscribers
- Avg views / post
- 298
- 20 posts measured
- Reaction rate
- —
- this channel exposes no reaction counts
- Posts in window
- 20
- of 20 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 7 August 2026 |
|---|---|
| Posts held | 20 (4 August 2026 – 7 August 2026) |
| Views total | 5,964 |
| Reactions total | — |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 7 Aug 2026, 14:33 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
Recent posts
[8/7 큐라클 소식]CU01 용도특허 일본 출원 완료 안녕하세요. 당사는 국내와 미국 등에 이어 일본에서도 CU01 당뇨병성 신증 임상 2b상 결과를 기반으로 한 신규 용도특허 출원을 완료했습니다. 이번 특허는 CU01을 SGLT-2 억제제 등 기존 당뇨병성 신증 치료제와 병용하는 치료 방법에 관한 것으로, 임상 2b상 병용 투여군에서 확인된 단백뇨 개선 효과를 바탕으로 출원됐습니다. 특허가 등록될 경우 출원일로부터 20년간 해당 용도에 대한 독점적 권리를 확보할 수 있어, CU01의 후속 개발과 사업화에 중요한 기반이 될 것으로 기대합니다. 당사는 앞으로도 주요 국가에서 특허 권리를 지속적으로 확보해 CU01의 개발과 사업화를 추진해 나가겠습니다. 감사합니다. https://www.curacle.com/bbs/board.php?…
https://www.thebionews.net/news/articleView.html?idxno=27005
안녕하세요, 에스바이오메딕스입니다. 파킨슨병 세포치료제 TED-A9의 미국 임상 3상과 관련하여 진행한 FDA Type C 절차가 완료되어 안내드립니다. ▶ 진행 경과 당사는 지난 5월 미국 FDA에 Type C 미팅을 신청하여, 7월 말 화상회의가 예정되어 있었습니다. 회의에 앞서 당사가 사전에 제출한 Type C 미팅 패키지(Meeting Package) 및 질의 전반에 대해 FDA로부터 예비 서면답변(Preliminary Written Response)을 수령하였습니다. 이와 함께 FDA는 해당 답변이 충분히 명확하여 추가 논의가 필요하지 않다고 판단될 경우, 이를 알려줄 것을 안내하였습니다. 그 경우 해당 답변이 Type C에 대한 FDA의 최종 공식 답변으로 확정된다는 점을 명시했습니다. 당사는 답변 내용이 충분히 명확하고 …
#컴패스 #에이비엘바이오 이번 분기 중 FDA로부터 COMPANION-002 임상 2/3상 데이터에 대한 피드백을 받을 예정이며, 결과에 따라 올해 말 BLA 제출 가능성이 있음. 최종 분석에서 토베시미그 병용군 ORR은 18.0%, 파클리탁셀 단독군은 5.3%로 통계적 유의성을 확보함. 전체 임상 데이터는 2026년 10월 ESMO에서 구두 발표로 공개될 예정. https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2026-second-quarter-financial
일본 정형외과 전문의가 5일 큐렉소 본사를 방문하고 서울 부민병원에서 인공고관절 전치환술 CUVIS-joint THA(Total Hip Arthroplasty) 로봇 수술을 참관했습니다. 이를 통해 실제 임상 환경에서의 수술 워크플로우와 시스템 활용 사례를 확인하는 시간을 가졌습니다. 이번 방문은 일본 시장에서 CUVIS-joint THA 적응증 확대를 위한 의료진 교육 및 임상 교류의 일환으로 진행됐습니다. 큐렉소는 지난해 3월 일본에서 CUVIS-joint TKA(인공무릎관절 전치환술) 의료기기 인허가를 획득했으며 이번 현장 참관을 통해 일본 의료진의 THA 시스템에 대한 이해를 높이고 임상 경험을 공유했습니다. 앞으로도 당사는 일본 의료진과의 협력을 강화하며 CUVIS-joint의 적응증 인허가 확대와 일본 시장 내 사업 기반을 …
Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses 🏛️ 규제 | 🔴 HIGH Revolution Medicines(NASDAQ:RVMD)는 췌장암 치료제 daraxonrasib의 미국 및 유럽 승인 결정을 기다리며 출시 준비에 돌입했다. 동사 경영진은 해당 약물이 업계에서 가장 주목받는 임상 단계 치료제 중 하나라고 밝혔으며, 전이성 췌장암 적응증에 대한 규제 승인 심사가 진행 중이다. 출시 준비에 따라 2026년 운영 비용 가이던스를 상향 조정했다. 📌 원문: https://endpoints.news/revolution-medicines-preps-for-launching-pancreatic-cancer-drug-ups-2026-exp…
수술로봇 커지는데 제도는 제자리…수가 현실화가 관건 https://www.dailypharm.com/user/news/340962
릴리 어닝콜 발언 "주사제에 대한 선호가 상당히 높아서, 약 80% 정도가 주사제를 사용중" 부작용 덜한 스마트데포 월1회 주사제 나오면 더 압도적일듯
오는 9월 30일 EADV학회에서 APB-R3 2a상 탑라인 결과발표가 예정되어있습니다. 제목이 ‘positive’ data발표라는 점이 눈에 띕니다.
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer 🧬 임상시험 | ⚪ LOW SystImmune(Biokin 자회사)은 BL-M14D1(DLL3 표적 ADC, brengitecan 플랫폼)과 atezolizumab 병용요법을 평가하는 글로벌 Phase 3 등록임상 BrenDeLL-Lung01(NCT07625644)에 첫 환자를 투여했다고 발표했다. 대상은 이전 치료 이력이 없는 extensive-stage 소세포폐암(ES-SCLC) 환자이며, 대조군은 표준치료인 백금 기반 요법 + etoposide 유도 후 atezolizumab 유지(±lurbinecte…
와이바이오로직스는 최대주주인 박영우 각자대표가 최근 2차례에 걸쳐 자사주 4900주를 장내 매수했다고 공시했습니다. 이로써 박 대표의 와이바이오로직스 보유 주식수는 354만2522주(지분율 23.05%)로 늘어나게 됐다. https://www.thebionews.net/news/articleView.html?idxno=26958
Showing the 12 most recent of 20 posts we hold for @IVResearch. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank
Citation-graph rank — 411,901 of 1,160,990entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Republishes
Channels on the register whose posts this channel has forwarded.
@BiopharmaBot_News · 1062 posts바이오스펙테이터
@biospectatorT · 5,8782 posts큐라클(365270) IR/PR 공식채널
@curacle · 3832 posts알테오젠 IR
@alteogenIR · 9,5861 post에이프릴바이오 IR채널: 리레이팅 2026
@aprilbioipr · 4,4081 post[신한 리서치본부] 제약/바이오
@bio_shinhan · 21,2461 post큐렉소(060280) IR & PR 공식채널
@curexo · 3071 post작업중이양
@eyang92 · 7,2011 post지아이이노베이션 공식 IR
@GIInnovation · 1,8961 post아이엠바이오로직스 IR/PR
@imbiologics_official · 4971 post인벤티지랩 IR
@InventagelabIR · 1,1711 post제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,8791 post에스바이오메딕스 • S.BIOMEDICS • official
@sbiomedics · 1,3151 post더바이오 뉴스룸
@thebio111 · 6,4911 post
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 11 August 2026 — this entry's latest reading, not the date you are reading this.
“[IV Research]” (@IVResearch), 2,474 subscribers as measured 11 August 2026. Telegram Register, tgregister.com/channel/IVResearch.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.